GlassScriptPhysician profile
Matthew A Nash
NPI 1740257930
$4,141.37
in general payments reported to CMS, 2019-2025
34 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $218 · 2021: $467 · 2022: $925 · 2023: $488 · 2024: $295 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.73 |
| Education | $153.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.68 | 2019-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $488.15 | 2019-2023 | |
| Abbvie INC. | $468.29 | 2019-2023 | |
| Pfizer INC. | $401.61 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $232.62 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $207.09 | 2023-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $183.68 | 2022 | |
| Agile Therapeutics, INC. | $153.13 | 2021-2023 | Twirla |
| Aspira Women'S Health INC | $143.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $117.59 | 2019-2025 | Injectafer |
| Exeltis, USA INC. | $98.79 | 2021-2024 | Slynd |
| Hologic Sales and Service, LLC | $96.85 | 2019-2025 | Aptima |
| Millicent US INC | $95.27 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Coopersurgical, INC. | $93.86 | 2021-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $83.25 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.74 | 2019-2024 | Gardasil, Gardasil 9 |
| Channel Medsystems, INC. | $69.87 | 2022-2023 | |
| Myovant Sciences INC. | $57.62 | 2022 | |
| Baxter Healthcare | $56.78 | 2025 | Tisseel |
| Richard Wolf Medical Instruments Corp. | $44.97 | 2019 | |
| Scynexis, INC. | $43.52 | 2022 | |
| Exact Sciences Corporation | $41.82 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $37.55 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $36.89 | 2022-2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $29.22 | 2019 | |
| Medtronic, INC. | $26.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.40 | 2021 | |
| Smith+Nephew, INC. | $19.40 | 2025 | Stravix Pl |
| Medicem INC. | $17.10 | 2021 | |
| Boston Scientific Corporation | $16.91 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.87 | 2019 | |
| Avion Pharmaceuticals | $12.92 | 2021 | |
| Allergan, INC. | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.